Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,262 across all filing types
Latest filing 2025-03-19 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
关于使用闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by a company (葵花药业集团股份有限公司) regarding the progress of using idle self-owned funds for cash management. It details the amounts invested, types of financial products purchased, risk control measures, and the impact on the company. The document is structured as a formal announcement with tables of financial product details and risk disclosures. It does not contain comprehensive financial statements or detailed financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is not a report publication announcement since it contains substantive information about the cash management activities. The document is an update on financing activities related to cash management and investment of idle funds, which fits the category of Capital/Financing Update (CAP).
2025-03-19 Chinese
关于使用闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by a company (葵花药业集团股份有限公司) regarding the progress of using idle self-owned funds for cash management. It details the amounts invested, types of financial products purchased, risk control measures, and the impact on the company. The document is structured as a formal announcement with tables of investment details and risk disclosures. It does not contain comprehensive financial statements or detailed financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is not a certification, call transcript, or management report. The document is longer than 5,000 characters and provides substantive information about financing activities related to cash management and investment of idle funds. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including cash management and investment of idle funds.
2025-03-04 Chinese
关于变更签字注册会计师的公告
Audit Report / Information Classification · 95% confidence The document is an announcement from a company about the change of its signing certified public accountant (CPA) for the audit of its 2024 financial report and internal control report. It mentions the appointment of a new signing CPA replacing the previous one, with details about the new CPA's qualifications and independence. The document does not contain any financial statements or substantive financial data itself, nor is it a full audit report. It is a formal announcement related to audit personnel changes, which fits the category of Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or audit report itself. The document length is short (1268 characters), and it is not merely announcing the publication of a report but announcing a change in audit personnel. Therefore, the best classification is AR (Audit Report / Information). FY 2024
2025-02-07 Chinese
关于使用闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by a company (葵花药业集团股份有限公司) regarding the progress of using idle self-owned funds for cash management. It details the amounts invested, types of financial products purchased, risk control measures, and the impact on the company. The document is structured as a formal announcement with tables of investment details and risk disclosures. It does not contain comprehensive financial statements or detailed financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is not a call transcript, audit report, or any other specialized report. The document is a regulatory announcement about financing activities related to cash management and investment of idle funds, which fits best under Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive information about financing activities, not just a brief notice or certification, so it is not RPA or RNS. Therefore, the classification is CAP with high confidence.
2025-01-24 Chinese
2024年年度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a 2024 annual performance forecast (业绩预告) for the full year 2024, covering the period from January 1, 2024 to December 31, 2024. It provides preliminary estimated financial results such as net profit and earnings per share, with explanations of performance changes and risk warnings. It explicitly states that the data is preliminary, unaudited, and subject to the final 2024 annual report. The document length is short (1092 characters) and it is a forward-looking earnings forecast rather than a full financial report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements and detailed analysis. It is not a Report Publication Announcement (RPA) because it contains substantive financial estimates and explanations, not just a notice of report availability. Therefore, the correct classification is Earnings Release (ER). FY 2024
2025-01-17 Chinese
关于对子公司增资的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of capital increase in a subsidiary company. It details the board meeting decision, the registration of the subsidiary's new business license, and the updated shareholding structure. The document is short (1073 characters) and focuses on a specific corporate action related to capital investment in a subsidiary. It does not contain financial statements or detailed financial performance data. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2025-01-07 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.